Lexaria Bioscience Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LEXX | MTVA | LPCN | BDRX | NIKI | JAGX | |
|---|---|---|---|---|---|---|
| Market cap | 6.89M | 9.55M | 13.69M | 844.66K | 9.42M | 9.03M |
| P/E (TTM) | — | — | — | 0.0 | — | — |
| Forward P/E | -8.4 | — | -1.3 | — | — | -0.8 |
| Price/book | 1.1 | 1.4 | 0.6 | 0.0 | 0.1 | 3.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −75.49% | −87.07% | −44.69% | −99.09% | −74.68% | −99.57% |
| Today | −1.51% | +2.84% | −3.49% | −16.73% | −24.50% | −3.13% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LEXX news ›Expanded funding for four diabetes drugs
Pharma in Focus Connecting you with your industry every day Expanded funding for four diabetes drugs Up to 30,000 extra New Zealanders could have funded access to type 2 diabetes medications with Pharmac expanding the eligibility criteria…
Universal Standard’s x Abisola collab makes a business case for size inclusion amid the GLP-1 boom
As GLP-1 drugs alter customers’ bodies and shopping habits, Universal Standard is betting that fluctuating sizes make inclusive fashion more relevant, not less. The brand launched US x Abisola, a seven-piece capsule created with…
Lexaria Bioscience Corp. Launches New Study to Examine Next-Generation Glp-1 Drugs
Lexaria Bioscience Corp. contracted the contract research organization to execute and report on its 2026 Animal Study #2 that will evaluate a number of formulation enhancements with 2 next-generation... contracted the contract research…
Lexaria Bioscience Corp. Provides Update on Oral Glp-1 Drug Strategy and Dehydratech Platform Enhancements
Published on 03/24/2026 at 10:41 am EDT Lexaria Bioscience Corp. provides this update ofdevelopments within the glucagon-like peptide-1 ("GLP-1") market. Lexaria has been listening and responding to the concerns of those using GLP-1 drugs,…
Lexaria Bioscience Corp. Begins Dosing in Animal Study GLP-1-A26-1 and Receives Additional New Granted Patent
Lexaria Bioscience Corp. provided an update on Animal Study #1 that is evaluating a number of formulation enhancements using both DehydraTECH-semaglutide glucagon-like peptide-1 compositions and...
Lexaria Bioscience Corp.: Official Announcements - Stock Market News
Find the latest press releases and official documents published by Lexaria Bioscience Corp. on MarketScreener. Press Releases Lexaria Bioscience Corp. All financial news and data tailored to specific country editions
All Transcripts on Lexaria Bioscience Corp. (LEXX)
Find all the latest transcripts on Lexaria Bioscience Corp. Transcripts Lexaria Bioscience Corp. All financial news and data tailored to specific country editions
Lexaria Bioscience Corp. : Insider Transactions
Follow insider transactions on Lexaria Bioscience Corp. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Lexaria Bioscience Corp. Latest insider transactions for Lexaria…
Lexaria Bioscience Corp.: News in other languages | LEXX | US52886N6040
Lexaria Bioscience Corp.: News, information and stories for Lexaria Bioscience Corp. | Nasdaq: LEXX | Nasdaq Other languages Lexaria Bioscience Corp. All financial news and data tailored to specific country editions
Lexaria Bioscience Corp. Updates Progress on Human Study #7
Published on 05/05/2026 at 10:27 am EDT Lexaria Bioscience Corp. provided this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide (?DHT-sema?) compositions against Novo Nordisk?s commercially…
From articles in the 4Search news index.
In the news
Mentioned with
Most coverage from
-
marketscreener.com12
-
confectionerynews.com1
-
foodnavigator.com1
-
pharmainfocus.com.au1
-
stocktitan.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.